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Abstract
Background: Grape and blueberry extracts are known to protect against age-related cognitive decline. However,
beneficial effects achieved by mixing grape and blueberry extracts have yet to be evaluated in dogs, or their
bioavailability assessed. Of concern to us were cases of acute renal failure in dogs, after their ingestion of grapes or
raisins. The European Pet Food Industry Federation (2013) considers only the grape or raisin itself to be potentially
dangerous; grape-seed extracts per-se, are not considered to be a threat. Our aim was therefore to evaluate the
renal and hepatic safety, and measure plasma derivatives of a polyphenol-rich extract from grape and blueberry
(PEGB; from the Neurophenols Consortium) in dogs. Polyphenol expression was analyzed by UHPLC-MS/MS over
8 hours, for dogs given PEGB at 4 mg/kg. Safety was evaluated using four groups of 6 dogs. These groups received
capsules containing no PEGB (control), or PEGB at 4, 20, or 40 mg/kg BW/d, for 24 weeks. Blood and urine samples
were taken the week prior to study commencement, then at the end of the 24-wk study period. Routine markers of
renal and liver damage, including creatinine (Creat), blood urea nitrogen, albumin, minerals, alkaline phosphatase
(ALP), and alanine transaminase (ALT) were measured. Biomarkers for early renal damage were also evaluated in
plasma (cystatin C (CysC), and neutrophil gelatinase-associated lipocalin (NGAL)), and urine (CysC, clusterin (Clu),
and NGAL). Ratios of urinary biomarkers to Creat were calculated, and compared with acceptable maximal values
obtained for healthy dogs, as reported in the literature.
Results: While several PEGB-specific polyphenols and metabolites were detected in dog plasma, at the end of the
PEGB consumption period, our biomarker analyses presented no evidence of either renal or liver damage (Creat,
BUN, ionogram, albumin and ALT, ALP). Similarly, no indication of early renal damage could be detected. Plasma
CysC, urinary CysC/Creat, Clu/Creat, and NGAL/Creat ratios were all beneath reported benchmarked maximums,
with no evidence of PEGB toxicity.
Conclusions: Long-term consumption of a pet specific blend of a polyphenol-rich extract from grape and
blueberry (PEGB; from the Neurophenols Consortium), was not associated with renal or hepatic injury, and can
therefore be considered safe.
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Background
This work comprises part of a project dedicated to the
study of age-related cognitive decline in humans and
dogs (the Neurophenols Consortium). We aim to
complete a novel study into the efficacy of mixed extracts
of grape and blueberry in counteracting age-related
deterioration of function. In aged dogs, polyphenol inges-
tion (including grape pomace), and vitamin use, are both
thought to ameliorate the effects of aging on learning abil-
ity [1]; similarly beneficial effects have been reported for
humans [2]. A popular hypothesis is that protection
against oxidative stress explains these effects. In aged
mice, the consumption of a mixed grape and blueberry ex-
tract, has also been shown to improve spatial navigation;
one of the skills that declines with age. In this scenario, in-
creased expression for hippocampal nerve growth factor
mRNA [3] may play a causal role [4].
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Studies reporting grape extract consumption in dogs
(using grape seed and skin extracts, or grape seed
proanthocyanidins), or grape pomace in aged dogs have,
to date, not reported any side effects [1, 5, 6]. However,
acute renal failure has been reported in dogs after their
consumption of grapes, with kidney histopathology re-
vealing tubular degeneration leading to necrosis, particu-
larly in the proximal tubule [7–9]. In a retrospective
study involving a cohort of 43 dogs, all of whom had
eaten grapes, raisins, or both, animals presented with
clinical signs consistent with kidney deterioration during
a window extending from 24 h, until 5 days, after con-
sumption. Vomiting, diarrhea, lethargy, and either olig-
or, anuria, were the common clinical signs. A diagnosis
of renal damage was supported by biochemical abnor-
malities showing higher plasma creatinine (Creat), blood
urea nitrogen (BUN), an altered ionogram, glycosuria,
and proteinuria. Again, histopathology revealed severe
diffuse renal tubular degeneration, especially in proximal
cells, with glomerular deterioration. Half of the dogs
died [9]. In these cases, the precise amount of fruit eaten
varied greatly (from 3 g/kg BW of raisin, to 150 g/kg
BW of grape), as did the type of fruit (grape, raisin,
seedless grape), and the affected breed [7–9]. Hepatic
toxicity has also been associated with the consumption
of plants such as greater celandine, green tea, valerian,
or ayurvedic products. In these cases, higher concen-
trations of alanine transaminase (ALT), alkaline phos-
phatase (ALP), aspartate aminotransferase (AST), and
bilirubin, were all demonstrated (reviewed in [10, 11]).
Abnormal values of ALT and ALP provoked by grape
consumption also point to the liver being a target of
grape toxicity [9], although the factors responsible for
hepatic damage, as well as the acute renal failure, have
yet to be identified.
The Neurophenols Consortium is a Europe-North
America research collaboration dedicated to the re-
search, and development of natural ingredients and
products to prevent age-related cognitive decline in
humans and pets. The Consortium brings together sci-
entists in the fields of phytochemistry, neuroscience,
psychology and nutrition with companies specialized in
the development of active ingredients and food supple-
ments. The specific aims of the program are to
characterize and formulate fruit extracts from blueberry
and grape, to evaluate their safety and efficacy in pre-
clinical and clinical trials.
The aim of this study was to assess the safety of a
polyphenol-rich extract from grape and blueberry
(PEGB; from the Neurophenols Consortium). We stud-
ied the safety of this extract following chronic use in
dogs, by monitoring renal and hepatic health, using




Twenty-four experimental Beagle dogs (4 groups of 5
males, and a single female, body condition score (BCS)
5/9, mean age 31 ± 3 months, mean body weight (BW)
11.4 ± 0.2 kg), originally from CEDS (Centre d’élevage
du Domaine des Souches, Mézilles, France), were used.
They were fed with a dry maintenance diet (Medium
Adult Royal Canin), according to the National Research
Council (NRC 2006) [12] recommendation (130 kcal
metabolizable energy per kg metabolic body weight).
Study design
Four groups of 6 dogs (each comprising 5 males and a
female) were given a polyphenol-rich extract from grape
and blueberry (PEGB) for 24 weeks. The constituents of
this PEGB extract were devised by the Neurophenols
Consortium; these were grape (Vitis vinifera L.), and
blueberry (Vaccinium angustifolium) extracts, containing
specific polyphenols with low molecular weight mono-
mers, including catechin (6 % dry matter), oligomers, fla-
vonols (for a total of 0.15 % dry matter), anthocyanins,
phenolic acids, and resveratrol formulated in a unique
ratio of molecules. The intended dosage was 4 mg/kg
BW/d. One group also received a control dose of
0 mg/kg BW/d (control), with two other groups receiving
higher doses of the extract; 20 mg/kg BW/d, and 40 mg/kg
BW/d. Each dose was given in the daily meal as a gelatin
capsule (Cooper, Melun Cedex, France) containing the for-
mulation and maltodextrin. All extracts were prepared in
accordance with good laboratory practices.
Plasma and urine samples
Blood and urine samples were collected in the week
prior to the study commencing, and then at the end of
the 24-wk period. Blood samples were obtained by jugu-
lar venipuncture into heparin tubes in 24-hour unfed
animals. Each blood draw was immediately centrifuged
(2124 g for 10 min at 4 °C), and the plasma fraction ali-
quoted and frozen at -80 °C. Twenty-four-hour urine
samples were collected by voiding, following the con-
sumption of the daily meal and the capsules. The ex-
pression of specific polyphenols, derived from the PEGB
extract, were measured, on the 8th days of exposure, in
plasma samples from dogs that were given PEGB at
4 mg/kg/d. For this purpose, plasma samples were taken
for 8 h, with polyphenol analyses performed by UHPLC-
MS/MS.
Chemical analyses
Concentrations of Creat, BUN, minerals (sodium (Na+),
potassium (K+), calcium (Ca2+), and phosphate (PO4
3-),
albumin, ALT, and ALP, were determined using a VetS-
can reagent rotor (Comprehensive Diagnostic Profile,
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VetScan VS2, Abaxis, Ca, USA). Biomarkers of renal
damage, including CysC (cystatin C), Clu (clusterin), and
NGAL (neutrophil gelatinase-associated lipocalin), were
measured by species-specific ELISA (canine cystatin C,
Biovendor, Czech Republic; canine clusterin, Biovendor,
Czech Republic; dog NGAL, Bioporto, Denmark). Urinary
Creat was assayed using an enzymatic colorimetric kit
(Creatinine, Randox Laboratories, UK).
Data analyses
Results are reported as means ± standard error of the
mean (SEM). For each early biomarker of renal damage,
we compared their maximal values after PEGB con-
sumption with previous maximal values reported for
healthy dogs. As replicate datasets were collected, linear
mixed-effects model analyses could be undertaken to in-
vestigate any interaction between PEGB dose, and time.
Moreover, an inter-group analysis was performed using a
linear model to compare data for each of the experimen-
tal groups (4, 20, and 40 mg/kg/d), with the control
group, at the beginning and end of the study. Finally, an
intra-group analysis was completed using a linear mixed
effects model to compare data from the initiation and
end of the study. These analyses were completed using
the R software (R Core Team (2013)). The alpha level
for determination of significance was 0.05.
Results
Specific polyphenols in plasma following PEGB
consumption
Polyphenols and their metabolites were detected in
plasma samples, and their maximum concentrations
(Cmax) determined. These metabolites comprised: hy-
droxy and dihydroxyphenyl-γ-valerolactone, both de-
rived from flavan-3-ols; the resveratrol derivatives,
reseveratrol glucuronide, dihydroresveratrol sulfate, and
glucuronide; the flavonol and its metabolite, quercetin
and isorhamnetine sulfate; and the anthocyanin metabol-
ite, malvidin. A Cmax for the flavan-3-ol metabolites of
2028 nM was attained after 8 h. Flavonol metabolites
reached a Cmax of 5nM, also after 8 h, with malvidin
also peaking (7nM) at this timepoint. Peak concentra-
tions for resveratrol metabolites were reached much
earlier, after 30 min (Cmax 161 nM).
Plasma and urine biomarkers
Markers of liver damage
Plasma hepatic biomarker concentrations are shown in
Table 1. All ALT and ALP concentrations were within
the reference range.
Markers of renal damage
Plasma creatinine, urea, sodium, potassium, calcium,
phosphate, and albumin concentrations are shown in
Table 2. All values were found to be in the reference
range, i.e. the 95 % prediction interval (for a normal
population).
The concentration of early renal biomarkers, and their
ratios, are presented in Table 3. For each biomarker,
interaction analyses failed to identify any difference be-
tween the experimental and control groups, either at the
beginning, or at the end of the study. No inter-group or
intra-group variations could be noted between experi-
mental groups, compared to controls, or between the
initiation and the end of the study.
In the experimental groups (PEGB given at 4, 20 or
40 mg/kg/d), the mean plasma CysC concentrations
were found to be similar to control group. Mean con-
centrations ranged from 1.2 to 1.5 μg/mL (Fig. 1a).
Intra-group analyses also showed no differences across
the experimental groups. Collectively, their mean urinary
CysC/Creat ratio varied from 4 to 27 μg/g. These ratios
were not significantly different to those determined for
the control group, for whom no intra-group difference
was noted (Fig. 1b). Mean urinary Clu/Creat ratios var-
ied between 44 and 94 ng/g in groups given PEGB at 4
to 40 mg/kg/d, again with no significant changes com-
pared to control group nor intra-group differences be-
tween the initiation and the end of the study (Fig. 2).
The mean urinary NGAL/Creat ratios were similar to
control group in the experimental groups, varying be-
tween 4 and 8 ng/g. Intra-group analyses also failed to
determine any significant differences between the initi-
ation and the end of the study (Fig. 3).
Discussion
Our aim was to assess the safety of a polyphenol-rich ex-
tract from grape and blueberry (PEGB; from the Neuro-
phenols Consortium) for dogs, by monitoring early
biomarkers of renal damage over a 24-week period. This
work considerably extends the previous study periods
reported, where platelet effects, and gene expression
profiles, were interrogated after 7 days, or 3 months of
supplement use [5, 6].
After PEGB consumption, biomarker values exceeded
the reported maximal limits in no dog, with no differ-
ences observed at the end of the 24-week period, com-
pared to beginning, for plasma CysC, and urinary CysC/
Creat, Clu/Creat, or NGAL/Creat ratios. When consid-
ering these data, we conclude that the dogs neither pre-
sented with renal, nor hepatic injury, at the end of the
study.
While bioavailability of the Neurophenols Consortium
PEGB had never been evaluated in dogs, our evaluation
of the safety of this supplement necessitated measure-
ment of PEGB derivatives in plasma. The main polyphe-
nols in the extract were flavan-3-ols, resveratrol,
anthocyanins (malvidin, petunidin, peonidin, petunidin,
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Table 1 Plasma biomarkers of kidney damage in dogs, at the initiation (Week -1) and the end (Week 24) of a 24-wk period of consumption of PEGB at 4, 20 or 40 mg/kg/d.




4 mg/kg/d 20 mg/kg/d 40 mg/kg/d
Week -1 Week 24 Week -1 Week 24 Week -1 Week 24 Week -1 Week 24
Creatinine (0.3–1.4) mg/dL 0.8 ± 0.1 (0.4–1.0) 0.8 ± 0.1 (0.5–1.0) 0.9 ± 0.1 (0.7–1.1) 0.7 ± 0.1 (0.6–0.9) 0.8 ± 0.1 (0.5–1.1) 0.8 ± 0.1 (0.5–1.3) 0.9 ± 0.1 (0.7–1.1) 0.8 ± 0.1 (0.5–0.9)
Blood urea
nitrogen (7–25)
mg/dL 14 ± 1 (11–15) 13 ± 1 (10–15) 12 ± 1 (8–15) 11 ± 1 (7–14) 10 ± 1 (8–10) 9 ± 1 (7–13) 12 ± 1 (10–17) 12 ± 1 (9–15)
Sodium (138–160) mmol/L 145 ± 2 (138–150) 142 ± 2 (137–147) 146 ± 2 (138–152) 142 ± 2 (136–148) 147 ± 1 (143–151) 142 ± 1 (138–146) 145 ± 1 (143–147) 146 ± 2 (140–151)
Potassium (3.7–5.8) mmol/L 4.7 ± 0.1 (4.4–5.1) 4.7 ± 0.3 (3.7–5.4) 4.4 ± 0.1 (3.8–4.7) 4.6 ± 0.2 (3.6–5.0) 4.5 ± 0.1 (4.2–4.9) 4.5 ± 0.2 (3.9–5.1) 4.6 ± 0.1 (4.4–4.9) 4.8 ± 0.3 (4.0–5.8)
Calcium (8.6–11.8) mg/dL 10.1 ± 0.2 (9.4–10.5) 10.1 ± 0.1 (9.8–10.7) 10.7 ± 0.2 (9.8–11) 10.4 ± 0.1 (10.0–10.8) 10.5 ± 0.3 (9.6–11.2) 10.4 ± 0.2 (9.8–10.8) 10.5 ± 0.1 (10.1–10.9) 10.5 ± 0.1 (10.1–10.8)
Phosphate (2.9–6.6) mg/dL 4.3 ± 0.2 (3.6–5.0) 4.2 ± 0.3 (3.3–4.9) 4.5 ± 0.3 (3.9–5.8) 4.4 ± 0.3 (3.3–5.2) 4.2 ± 0.2 (3.4–5.1) 4.4 ± 0.3 (3.6–5.1) 4.4 ± 0.2 (3.4–5.1) 4.2 ± 0.1 (3.8–4.6)













cyanidin), and flavonol (quercetin). Some polyphenols
and polyphenol metabolites were found in plasma.
Malvidin, which is present in blueberry but not in grape,
has been the only anthocyan detected, but it is known
that anthocyanins are less absorbed than other flavo-
noids. The finding of resveratrol derivatives (which are
grape specific) is in accordance with a study that also
showed appearance of resveratrol conjugates (sulfate &
glucuronide) in the plasma of dogs after resveratrol ad-
ministration [13]. The valerolactones detected resulted
from the metabolization of flavan-3-ols by gut micro-
flora. Quercetin and isorhamnetin sulfate, which are
present in both fruits, were also found. Other com-
pounds may have been absorbed, but either they have
not been identified, or their concentration was under the
detection threshold, or they were rapidly metabolized
and excreted. Very few data on polyphenols pharmaco-
kinetics in dogs are available. Regarding resveratrol,
Cmax could not be compared since in previous report
[13] it was given to dogs at much higher doses than the
intended dose in the present study (200–1200 mg/kg/d,
compared to 4 mg/kg/d). When anthocyanins were given
to pigs at 1 to 4 % of the diet (w/w), several metabolites
were measured in liver, eye and brain while there were
not detected in plasma [14], and again the doses were
far higher than in the present study. Catechin and epi-
catechin glucuronides from a grape extract given to mice
were measured in plasma [15], which was not the case
in our study, but the dose used was still much higher
(grape-derived polyphenols: 80 mg/kg/d). When green
tea catechins (13 mg/kg/d, [16], 170 mg/kg/d [17]) and
epigallocatechin gallate (EGCG; 250 mg/kg/d [18]) were
given to dogs, respective metabolites were found in
plasma, which was not the case after PEGB consumption
where only valerolactones were detected. The difference
could be explained either by the catechin sources or
higher doses or both. Another possible explanation is
that dogs were given the PEGB at the same time of their
daily meal, and the plasma measurements were done
after a relatively short period of exposure. Indeed in
dogs given EGCG at 300 mg/kg/d, plasma area under
the curve (AUC) for EGCG was higher in unfed than fed
dogs [19]. When EGCG was given at 500 mg/kg/d, au-
thors reported, although the difference did not reach the
significance level, that the AUC for EGCG was 1.6 time
higher after 28 days of dosing than after 14 days [19].
The data of the present study demonstrated that the
polyphenols of the PEGB extract were, at least in part,
bioavailable, and this is the first report on the appear-
ance of valerolactones as well as quercetin, isorhamnetin
sulfate and malvidin in the plasma of dogs after con-
sumption of a mixture of polyphenols.
The origin of the grape toxicity described in the litera-
ture for dogs is still obscure, but numerous hypotheses
have emerged. Among them, it was reported that ex-
ogenous compounds on grapes, such as mycotoxin, pes-
ticides, or herbicide residues, could be responsible for
the kidney toxicity, with histopathology indicating that
the proximal cells are the primary target [8]. These find-
ings provoked further hypotheses, such as the toxic ac-
cumulation of a foreign chemical (a xenobiotic), with a
particular affinity for tubular specific transporters. Add-
itionally, the expression of a perinuclear golden brown
pigment [8], could imply its cytotoxic accumulation,
with failed cellular clearance. Hypercalcemia and renal
mineralization induced by the high sugar content of
grapes are also current hypotheses.
The resveratrol concentration in grapes could also be
responsible for renal damage. A previous study described
that the no-observed-adverse-effect level of resveratrol
consumption was 600 mg/kg BW/d in dogs. Consump-
tion of twice this dose (1200 mg/kg BW/d) induced a
loss of appetite, and weight [20]. Given that grapes con-
tain 1.5 to 7.8 μg of total resveratrol per gram of fresh
weight [21], it is highly unlikely that resveratrol is re-
sponsible for the acute kidney injury observed in clinical
cases in dogs.
Plasma creatinine and urea are the most frequently
measured parameters used to evaluate renal damage.
High creatinine concentrations are seen when at least
75 % of renal function has already been lost [22]. In pre-
vious studies describing acute renal failure after grape
Table 2 Plasma biomarkers of liver damage in dogs, at the initiation (Week -1) and the end (Week 24) of a 24-wk period of






4 mg/kg/d 20 mg/kg/j 40 mg/kg/j








U/L 59 ± 9 (33–88) 63 ± 10 (32–86) 63 ± 6 (49–86) 65 ± 12 (51–126) 55 ± 9 (37–88) 57 ± 14 (33–109) 48 ± 7 (29–78) 49 ± 9 (20–80)
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Table 3 Concentrations, and ratios, of early biomarkers of renal damage in dogs, at the initiation (Week -1) and the end (Week 24) of a 24-wk period of consumption of PEGB at
4, 20 or 40 mg/kg/d. (Data are means ± SEM, n = 6/group; minima and maxima values are mentioned in parenthesis)
PEGB
Biomarkers Units Control 4 mg/kg/d 20 mg/kg/d 40 mg/kg/d
Week -1 Week 24 Week -1 Week 24 Week -1 Week 24 Week -1 Week 24
Plasma CysC μg/mL 1.2 ± 0.1 (1.0–1.6) 1.1 ± 0.1 (0.7–1.7) 1.3 ± 0.2 (0.6–1.7) 1.2 ± 0.2 (0.5–1.8) 1.2 ± 0.1 (0.9–1.5) 1.2 ± 0.1 (0.9–1.4) 1.5 ± 0.2 (1.1–2.2) 1.3 ± 0.1 (0.9–1.6)
Urinary CysC/Creat ratio μg/g 19 ± 17 (0–105) 14 ± 10 (0–62) 5 ± 4 (0–20) 4 ± 1 (0–9) 27 ± 14 (3–96) 21 ± 12 (3–79) 12 ± 4 (2–26) 4 ± 1 (0–9)
Urinary Clu/Creat ratio ng/g 79 ± 20 (7–134) 135 ± 66 (6–443) 44 ± 13 (3–99) 94 ± 69 (10–437) 63 ± 28 (6–170) 56 ± 25 (12–175) 84 ± 23 (18–163) 47 ± 20 (9–132)













consumption, symptoms appeared rapidly [9]. Therefore,
we reasoned that to monitor kidney health, earlier bio-
markers of renal damage would be required. In 2010, the
Nephrotoxicity Working Group established a consor-
tium between the European Medicines Agency, and the
Food and Drug Administration. They listed seven bio-
markers needed to detect the early development of renal
injury [23]. Among these, we chose to assess CysC and
Clu, because of their ease of use in dogs. In addition,
NGAL was measured, as a promising early biomarker of
drug-induced kidney injury. Collectively, these early bio-
markers of renal damage are ideal for monitoring renal
health, before irreversible damage, as they survey differ-
ent renal functions, and compartments of the kidney.
Ordinarily, cystatin C, which is a low molecular weight
protein produced at a constant rate by all cells, is
completely reabsorbed and catabolized in proximal
tubular epithelial cells [24]. Following renal injury, CysC
concentration increases in the plasma, as the glomerular
filtration rate declines [25]; an increased concentration
in urine reflects tubular impairment [26]. Plasma CysC
has previously been measured in healthy dogs (urea and
creatinine concentrations within reference intervals),
with the highest reported values of 2 μg/ml [27]. For all
dogs that had received PEGB, at any dose, plasma CysC
concentrations were beneath this upper limit. To the
best of our knowledge, the referenced study [27] is the
only one in which plasma CysC concentrations have
been measured in healthy dogs by canine ELISA. We
therefore conducted the same tests, in our study. In
other studies, CysC was measured in serum and/or with
Fig. 2 Urinary Clusterin/Creatinine ratio (ng/g) in dogs, at the initiation
( ) and the end ( ) of a 24-wk period of consumption of PEGB at 4, 20
or 40 mg/kg/d (n = 6 dogs per group). The line indicates the reported
maximal value in normal dogs
A
B
Fig. 1 a Plasma Cystatin C concentration (μg/mL) in dogs at the
initiation ( ) and the end ( ) of a 24-wk period of consumption of
PEGB at 4, 20 or 40 mg/kg/d (n = 6 dogs per group). The line indicates
the reported maximal value in normal dogs. b Urinary Cystatin
C/Creatinine ratio (μg/g) in dogs, at the initiation ( ) and the end
( ) of a 24-wk period of consumption of PEGB at 4, 20 or 40 mg/kg/
d (n = 6 dogs per group). The line indicates the reported maximal
value in normal dogs
Fig. 3 Urinary NGAL/Creatinine ratio in dogs (ng/g) before at the
initiation ( ) and the end ( ) of a 24-wk period of consumption of
PEGB at 4, 20 or 40 mg/kg/d (n = 6 dogs per group). The line indicates
the reported maximal value in normal dogs
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a different ELISA kit or technique (i.e. Particle-
Enhanced Turbidimetric Immunoassay), which may ex-
plain the slightly different reference ranges reported
[28–30]. In our study, the maximum urinary CysC/Creat
ratio that we measured in dogs following PEGB con-
sumption (regardless of dose) was 79 μg/g, whereas re-
ported urinary CysC/Creat ratios have been as higher
as 0.11 ± 0.02 mg/g [31]. Therefore, we conclude that
our CysC results revealed no glomerular or tubular
impairments.
Clusterin is a high molecular weight glycoprotein
expressed in epithelial cells (reviewed in [32]); in cases
of acute renal failure, clusterin is found at high concen-
trations in the urine, indicating glomerular damage [33].
The highest urinary Clu/Creat ratio previously reported
in healthy dogs was 4.87 μg/g [33]. In this study, the
urinary Clu/Creat ratio measured in dogs after PEGB
consumption (4 to 40 mg/kg/d) was far lower, ranging
from 10 to 437 ng/g. Therefore, clusterin analyses also
revealed no evidence of glomerular damage after PEGB
consumption.
NGAL is a protein that has raised some interest since
its mRNA and protein were detected in urine after in-
duction of acute kidney injury in rodents [34]. NGAL
mRNA has been found in the ascending limb of Henle,
and in collecting duct cells after ischemia-reperfusion
[35]. NGAL is ordinarily reabsorbed by the proximal tu-
bule [35, 36]. However, in case of renal injury, reabsorp-
tion may decrease, which results in higher urinary
concentrations. Tubular damage and reduced filtration
may also cause the accumulation of plasma NGAL [37].
The reported ranges of urinary NGAL/Creat ratio have
varied greatly in healthy dogs from 10 to 460 ng/g, or
from 40 to 3660 ng/g [38, 39]. These variations could re-
flect reporting from client-owned dogs of various breeds,
age, and gender, fed with various diets. In our study, the
urinary NGAL/Creat ratios after PEGB consumption (at
any dose), ranged from 0.9 to 10 ng/g, leading us to con-
clude that there was no evidence of tubular damage. Re-
cently, it was found that plasma NGAL was not an
absolute criterion with which to discriminate between a
healthy dog, versus a dog with either chronic, or acute
kidney disease [38] contrary to urinary NGAL [39] and
this shows how we must be cautious when interpreting
these values. Moreover, increasing plasma NGAL would
reflect tubular and filtration dysfunction, data already
provided by other early biomarkers of renal damage
(Plasma CysC, and urinary CysC/Creat, NGAL/Creat,
and Clu/Creat ratios). Therefore, we suggest that plasma
NGAL measurements represent redundant data and can
be omitted.
Intermediate measurements were also taken during
the 24-week study period for all biomarkers; these did
not reveal any significant differences.
The PEGB doses ranged from 4 to 40 mg/kg/d, the
intentional dose for dogs facing cognitive decline being
4 mg/kg/d [as recommended by the Neurophenols Con-
sortium]. In studies where dogs were fed supplements
with grape seed/skin extract at 20 mg/kg/d [5], or grape
seed proanthocyanidins at 5 mg/kg/d [6], symptoms re-
lated to acute renal failure were not reported. In the
group given the PEGB at 4 mg/kg/d, the dose of grape
extract was beneath these previously reported doses. In
addition, dogs consuming five or even ten times the
intentional PEGB dose, showed no alteration of kidney
or hepatic damage at 24 weeks. These data corroborated
the 2013 European Pet Food Industry Federation
(FEDIAF) advice that dogs could safely consume grape
extract.
We have considered why our extract, consumed long-
term, as described in this study, appears to be entirely
safe for consumption by dogs, in stark contrast to re-
ports of acute renal failure in pets following their con-
sumption of whole grapes or raisins. We can envisage
some possibilities. The extract developed by our consor-
tium is actually a complex mix of different extracts.
How these extracts are derived (i.e. extracted from the
grape), may have reduced, denatured, or eliminated, po-
tentially toxic compounds. These factors may underlie
the lack of any discernable toxicity when dogs consume
the Neurophenols Consortium extract, even at high
doses.
Conclusions
Following consumption of the PEGB at all doses, con-
ventional biomarkers of renal and liver damage were
within the reference range throughout the study, with
values of early biomarkers of renal damage CysC, Clu,
NGAL unremarkable. To our knowledge, this is the first
study demonstrating that chronic consumption of the
PEGB extract can be achieved with neither renal, nor
hepatic damage, at least based on plasma and urine ana-
lyses. Of note, renal health was monitored using a panel
of parameters encompassing both early biomarkers of
renal damage, as well as conventional biochemistry; this
complementary approach is recommended in future studies.
To conclude, dogs can safely consume a polyphenol-
rich extract from grape and blueberry (PEGB; from the
Neurophenols Consortium).
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